UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 216

Sortiert nach

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

HemaSphere, 2023-08, Vol.7 (S3), p.e85817f0-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

HemaSphere, 2023-08, Vol.7 (S3), p.e602412a-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

HemaSphere, 2023-08, Vol.7 (S3), p.e451088e-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

EJHaem, 2022-11, Vol.3 (4), p.1346-1351

2022

Link zum Volltext

Verfügbarkeit prüfen

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

HemaSphere, 2023-08, Vol.7 (S3), p.e20101d8

2023

Link zum Volltext

Verfügbarkeit prüfen

Erratum zu: Patient-Reported Outcomes in klinischer Praxis

Best practice onkologie, 2023-02, Vol.18 (1-2), p.59-60

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes in klinischer Praxis

Best practice onkologie, 2022-12, Vol.17 (12), p.636-646

2022

Link zum Volltext

Verfügbarkeit prüfen

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e551265b

2023

Link zum Volltext

Verfügbarkeit prüfen

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7068-7068

2023

Link zum Volltext

Verfügbarkeit prüfen

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S404-S404

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S194-S194

2023

Link zum Volltext

Verfügbarkeit prüfen

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Blood, 2020-11, Vol.136 (Supplement 1), p.17-18

2020

Link zum Volltext

Verfügbarkeit prüfen

Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib

International scholarly research notices, 2017, Vol.2017, p.1076493-6

2017

Link zum Volltext

Verfügbarkeit prüfen

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS7057-TPS7057

2021

Link zum Volltext

Verfügbarkeit prüfen

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7058-7058

2022

Link zum Volltext

Verfügbarkeit prüfen

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

Blood, 2020-11, Vol.136 (Supplement 1), p.44-45

2020

Link zum Volltext

Verfügbarkeit prüfen

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

Blood, 2021-11, Vol.138 (Supplement 1), p.3581-3581

2021

Link zum Volltext

Verfügbarkeit prüfen

POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S192-S192

2023

Link zum Volltext

Verfügbarkeit prüfen

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S390-S390

2023

Link zum Volltext

Verfügbarkeit prüfen

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Blood, 2022-11, Vol.140 (Supplement 1), p.6803-6805

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 216

Suche als RSS-Feed

Aktive Filter

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(196)
Mit Volltextzugriff
(209)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(15)
Science & Technology
(13)
Physical Sciences
(10)
Myelofibrosis
(8)
Patients
(6)
Technology
(6)
Materials Science
(5)
Materials Science, Multidisciplinary
(5)
Mpn
(5)
Physics
(5)
Adult
(4)
Aged
(4)
Anemia
(4)
Chemistry
(4)
Female
(4)
Hematology
(4)
Male
(4)
Middle Aged
(4)
Vitamin D
(4)
Analysis
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis

S213: BMS‐986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE‐ OR HIGH‐RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Erratum zu: Patient-Reported Outcomes in klinischer Praxis

Patient-Reported Outcomes in klinischer Praxis

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

POSTER: MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

The Incidence of Mastocytosis in Patients with Unclear Cytopenia and/or Leucocytosis: The Hryd Study

Consistency Test between Scoring Systems for Predicting Outcomes of Chronic Myeloid Leukemia in a Saudi Population Treated with Imatinib

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53 WT relapsed/refractory (R/R) myelofibrosis (MF)

Risk-adjusted safety analysis of pacritinib (PAC) in patients (pts) with myelofibrosis (MF)

An Open-Label, Global, Multicenter, Phase 1b/2 Study of KRT-232, a First-in-Class, Oral Small-Molecule Inhibitor of Murine Double Minute 2 (MDM2), Combined with Ruxolitinib in Patients Who Have Myelofibrosis and a Suboptimal Response to Ruxolitinib

A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2)

Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)

POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)

Updated Results from the Momentum Phase 3 Study of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated with a JAK Inhibitor

Transfusion Independence Response As a Potential Surrogate for Overall Survival in Jaki-Experienced Patients with Myelofibrosis from Momentum

Aktive Filter

Suchergebnisse filtern